Loading...
Solid Tumors2023-11-06T11:47:00+01:00

ESMO 2022 Solid Tumors – hybrid, Paris

Lecture Board: Myriam Chalabi, MD, PhD; Omid Hamid, MD; Jamie R. Merchan, MD; Armando Orlandi, MD, PhD; Matthias Pinter, MD, PhD
Medical Writer: Florence Boulmé, PhD; Eva Eckelhart, PhD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2022 – Solid Tumors

ESMO Solid Tumours 2022 English Slidekit

Slide Kit NSCLC, gastric cancer and other solid tumors

ESMO 2022 Solid Tumors English

Full report

EXPERT VIDEOS

All video interviews from ESMO Solid Tumors 2022

Stacey A. Cohen explains if ctDNA can detect MRD and predict recurrence in patients with colon cancer in a real-world setting, if it should be used in daily clinical practice or as a surveillance biomarker in stage II ctDNA-negative colon cancer patients. Moreover, she depicts how the treatment of patients with colon cancer might change in the foreseeable future.

ESMO 2021 Solid Tumors – virtual

Lecture Board: Daniel Catenacci, MD; Chiara Cremolini, MD, PhD; Sara A. Hurvitz, MD; Krishnansu S. Tewari, MD; Romain Varnier, MD;
Medical Writer: Florence Boulmé, PhD; Eva Eckelhart, PhD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2021

ESMO Solid Tumours 2021 cover

Slide Kit Lung and gastrointestinal cancers

ESMO 2021 Solid Tumors English

Full report (english)

Full report (mandarin)

EXPERT VIDEOS

All video interviews from ESMO Solid Tumors 2021

Yelena Y. Janjigian talks about the practice-changing results obtained in the CheckMate 649 trial and how the proportion of patients with advanced gastric cancer and esophageal adenocarcinoma who receive multiple treatment lines rather than just one or two can be increased. Biomarker-targeted therapies, precision medicine approaches for advanced G/GEJ cancers, the significance of chemotherapy as well as the duration of maintenance therapy are discussed, too.

Chiara Cremolini gives an overview of strategies that might become available in the future to enhance the efficacy of immunotherapies in the setting of microsatellite-stable metastatic colorectal cancer, how to increase the proportion of patients with metastatic colorectal cancer who receive multiple treatment lines, the optimal continuum of care in 2021 in metastatic colorectal cancer and how to predict progressive disease.

Javier Cortés highlights the superiority of trastuzumab deruxtecan compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and the resulting future therapy algorithm, potential combinations in the management of patients with HER2-negative breast cancer and the clinical relevance of immunotherapy-based approaches in the treatment of triple-negative breast cancer.

Ian Chau depicts the most interesting trial results in the field of esophageal cancer at the ESMO 2021 congress, gives an outlook on personalized approaches in the setting of esophageal squamous-cell carcinoma with regard to biomarkers for checkpoint inhibitors as well as potential further improvements of the prognosis of patients with esophageal cancer.

Ken Kato summarizes combination regimens currently investigated in the neoadjuvant treatment of patients with esophageal cancer and outlines how immunotherapy has changed the first-line treatment standards in patients with esophageal squamous-cell carcinoma and which further developments are expected for the first-and second-line setting in the future.

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Andrés Cervantes • MD • PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain

ESMO 2020 Solid Tumors – virtual

Lecture Board: Emiliano Calvo, MD, PhD; Andrés Cervantes, MD, PhD; Ronan Kelly, MD, MBA; Christian Schauer, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2020

ESMO Solid Tumours 2020 cover

Slide Kit PD-1/PD-L1 and PARP inhibition on GI and ovarian cancer

ESMO 2020 Solid Tumors English

Full report (english)

ESMO 2020 Solid Tumors Mandarin

Full report (mandarin)

EXPERT VIDEOS

All video interviews from ESMO Solid Tumors 2020

Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Andrés Cervantes • MD • PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain

ESMO 2019 – Solid Tumors Barcelona

Lecture Board: Hendrik-Tobias Arkenau, MD, PhD; Nicoletta Colombo, MD; Pascal Hammel, MD; Maha Hussain, MD; Paolo Nuciforo, MD, PhD; Bertrand Routy, MD, PhD; Gert Schachtner, MD; Christian Schauer, MD; Agostina Stradella, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO 2019

ESMO 2019 Solid Tumours English

Full report (english)

ESMO 2019 Solid Tumours Mandarin

Full report (mandarin)

EXPERT VIDEOS

All video interviews from ESMO 2019

Hendrik-Tobias Arkenau discusses combination studies of novel PARP inhibitors with other drugs.

Florian Lordick on the use of anti-PD-1 and other emerging therapies in gastric and oesophageal cancers.

Markus Möhler presents novel findings on anti-PD-1 therapies and explains differences regarding the outcome of anti-PD-1 therapies in Asian and Caucasian populations.

Simon Chowdhury talks about the use of PARP inhibitors in prostate cancer as well as the impact of pamiparib in patients with advanced solid tumors.

Over the last four years, we have reported from major conferences such as ASCO, ESMO, WCLC, ELCC or ESMO Asia on recent highlights in the field of lung cancer. Our congress reports and translations thereof into Mandarin and Japanese have received great international interest.

Alois Sillaber • Dr, Managing Director Springer-Verlag GmbH Springer Nature
Go to Top